See the published version of this preprint at Scientific Reports.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Kotaro Nagatsu
National Institutes for Quantum and Radiological Science and Technology
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
We developed a novel method for production of no-carrier-added (n.c.a.) [188, 189, 191Pt]PtⅡCl42- from an Ir target material, and then synthesized n.c.a. [*Pt]cis-[PtⅡCl2(NH3)2] ([*Pt]cisplatin) from [*Pt]PtⅡCl42-. [*Pt]PtⅡCl42- was prepared as a synthetic precursor of n.c.a. *Pt complex by a combination of resin extraction and anion-exchange chromatography after the selective reduction of IrⅣCl62- with ascorbic acid. The ligand-substitution reaction of Cl with NH3 was promoted by treating n.c.a. [*Pt]PtⅡCl42- with excess NH3 and heating the reaction mixture, and n.c.a [*Pt]cisplatin was successfully produced without employing precipitation routes. After this treatment, [*Pt]cisplatin was isolated through preparative HPLC with a radiochemical purity of 99+% at the end of synthesis (EOS).
Keywords
Platinum radionuclide, Auger electron, Cisplatin, Radiotheranostics, Iridium target, Resin extraction, Anion exchange chromatography
Figure 1
Figure 2
Figure 3
Figure 4
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Scientific Reports.
Version 1
Posted 10 Dec, 2020
No community comments so far
Editorial decision: Major revision
On 22 Feb, 2021
Reviews received
Received 29 Jan, 2021
Reviewers agreed
On 28 Jan, 2021
Reviewers invited
Invitations sent on 27 Dec, 2020
Editor assigned
On 27 Dec, 2020
Editor invited
On 08 Dec, 2020
Submission checks complete
On 08 Dec, 2020
First submitted
On 07 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nuclear Medicine & Medical Imaging
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Scientific Reports.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Kotaro Nagatsu
National Institutes for Quantum and Radiological Science and Technology
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Scientific Reports.
Version 1
Posted 10 Dec, 2020
No community comments so far
Editorial decision: Major revision
On 22 Feb, 2021
Reviews received
Received 29 Jan, 2021
Reviewers agreed
On 28 Jan, 2021
Reviewers invited
Invitations sent on 27 Dec, 2020
Editor assigned
On 27 Dec, 2020
Editor invited
On 08 Dec, 2020
Submission checks complete
On 08 Dec, 2020
First submitted
On 07 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nuclear Medicine & Medical Imaging
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Scientific Reports.
We developed a novel method for production of no-carrier-added (n.c.a.) [188, 189, 191Pt]PtⅡCl42- from an Ir target material, and then synthesized n.c.a. [*Pt]cis-[PtⅡCl2(NH3)2] ([*Pt]cisplatin) from [*Pt]PtⅡCl42-. [*Pt]PtⅡCl42- was prepared as a synthetic precursor of n.c.a. *Pt complex by a combination of resin extraction and anion-exchange chromatography after the selective reduction of IrⅣCl62- with ascorbic acid. The ligand-substitution reaction of Cl with NH3 was promoted by treating n.c.a. [*Pt]PtⅡCl42- with excess NH3 and heating the reaction mixture, and n.c.a [*Pt]cisplatin was successfully produced without employing precipitation routes. After this treatment, [*Pt]cisplatin was isolated through preparative HPLC with a radiochemical purity of 99+% at the end of synthesis (EOS).
Figure 1
Figure 2
Figure 3
Figure 4
Loading...